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Prostaglandin D2/J2 signaling pathway in a
rat model of neuroinflammation displaying
progressive parkinsonian-like pathology:
potential novel therapeutic targets
Chuhyon Corwin1, Anastasia Nikolopoulou3, Allen L. Pan1, Mariela Nunez-Santos1, Shankar Vallabhajosula3,
Peter Serrano2, John Babich3 and Maria E. Figueiredo-Pereira1*
Abstract
Background: Prostaglandins are products of the cyclooxygenase pathway, which is implicated in Parkinson’s disease
(PD). Limited knowledge is available on mechanisms by which prostaglandins contribute to PD neurodegeneration. To
address this gap, we focused on the prostaglandin PGD2/J2 signaling pathway, because PGD2 is the most abundant
prostaglandin in the brain, and the one that increases the most under pathological conditions. Moreover, PGJ2 is
spontaneously derived from PGD2.
Methods: In this study, we determined in rats the impact of unilateral nigral PGJ2-microinfusions on COX-2,
lipocalin-type PGD2 synthase (L-PGDS), PGD2/J2 receptor 2 (DP2), and 15 hydroxyprostaglandin dehydrogenase
(15-PGDH). Nigral dopaminergic (DA) and microglial distribution and expression levels of these key factors of the
prostaglandin D2/J2 pathway were evaluated by immunohistochemistry. PGJ2-induced motor deficits were assessed
with the cylinder test. We also determined whether oral treatment with ibuprofen improved the PD-like pathology
induced by PGJ2.
Results: PGJ2 treatment induced progressive PD-like pathology in the rats. Concomitant with DA neuronal loss in the
substantia nigra pars compacta (SNpc), PGJ2-treated rats exhibited microglia and astrocyte activation and motor
deficits. In DA neurons, COX-2, L-PGDS, and 15-PGDH levels increased significantly in PGJ2-treated rats compared
to controls, while DP2 receptor levels were unchanged. In microglia, DP2 receptors were basically non-detectable,
while COX-2 and L-PGDS levels increased upon PGJ2-treatment, and 15-PGDH remained unchanged. 15-PGDH
was also detected in oligodendrocytes. Notably, ibuprofen prevented most PGJ2-induced PD-like pathology.
(Continued on next page)
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Conclusions: The PGJ2-induced rat model develops progressive PD pathology, which is a hard-to-mimic aspect
of this disorder. Moreover, prevention of most PGJ2-induced PD-like pathology with ibuprofen suggests a positive
feedback mechanism between PGJ2 and COX-2 that could lead to chronic neuroinflammation. Notably, this is the
first study that analyzes the nigral dopaminergic and microglial distribution and levels of factors of the PGD2/J2
signaling pathway in rodents. Our findings support the notions that upregulation of COX-2 and L-PGDS may be
important in the PGJ2 evoked PD-like pathology, and that neuronal DP2 receptor antagonists and L-PGDS inhibitors
may be novel pharmacotherapeutics to relieve neuroinflammation-mediated neurodegeneration in PD, circumventing
the adverse side effects of cyclooxygenase inhibitors.
Keywords: Neuroinflammation, Cyclooxygenase, Prostaglandins, L-PGDS, DP2, 15-PGDH, Parkinson’s disease, PGD2/J2
signaling, Ibuprofen
Background
Neuroinflammation is activated upon CNS injury to
acutely initiate repair mechanisms, while chronic neuroin-
flammation can exacerbate, spread, and prolong CNS in-
jury. Chronic neuroinflammation plays a central role in PD
[1–5]. Critical to neuroinflammation is cyclooxygenase-2
(COX-2), which is highly induced in PD and negatively af-
fects neurons [6–8].
As far as we know, there are no models of PD that
utilize endogenous products of cyclooxygenases to mimic
the pathology of PD [9], besides our previous studies with
mice [10, 11]. PGD2 is the most abundant prostaglandin
in the brain [12–15], and it raises the most under patho-
logical conditions [16]. PGD2 is highly unstable (estimated
brain half-life of 1.1 min) [17], leading to spontaneous
non-enzymatic formation of PGJ2 [18]. Our rationale for
using PGJ2 to establish a rat model of neuroinflammation
is that we found that PGJ2 is highly neurotoxic compared
to PGD2 and PGE2 [19]. In contrast to PGD2 and PGE2,
PGJ2 and its metabolite 15d-PGJ2 bind covalently to pro-
teins through their α,β-unsaturated carbonyl groups [18].
In addition, J2 prostaglandins are uptaken by cells via a
carrier-mediated active transport, ending up in the cyto-
plasm and nucleus [20]. This endocytic transport is
unique to J2 prostaglandins, as it does not apply to PGD2
and E2 [20]. PGJ2 derivatives seem to activate the nuclear
peroxisomal proliferator activator receptor (PPARγ) [14],
and PPARγ agonists are being cautiously tested as
anti-inflammatory drugs to treated PD [21].
In rodents, the brain levels of PGJ2 are highly induced
upon stroke (cerebral ischemia) [15] and traumatic brain
injury (TBI) [22] reaching concentrations that are neuro-
toxic. Moreover, both stroke and TBI increase the
long-term risk for PD [23, 24]. We recently showed that
PGJ2-microinfusions into the brain induce PD-like path-
ology in mice [10, 11].
In neurons, PGJ2 upregulates COX-2 [25] potentially
establishing a positive feedback loop between PGJ2 and
COX-2 that could promote the transition from acute to
chronic neuroinflammation. To investigate whether
inhibiting cyclooxygenases diminishes the progressive
PD-like pathology induced by PGJ2, we administered
ibuprofen orally with food, to control (DMSO) and
PGJ2-treated rats. Ibuprofen is a non-steroidal anti-in-
flammatory drug (NSAID) that inhibits COX-1 and
COX-2, thus reducing the synthesis of all prostaglan-
dins [1]. Epidemiological studies support an inverse re-
lation between the use of ibuprofen and the risk of
developing PD [26, 27], with the risk reduction being
by as much as 50% [28]. However, clinical studies with
NSAIDs have not shown a similar trend, specifically for
Alzheimer’s disease (AD) [2, 28]. Thus, a better under-
standing of the shared and diverse mechanism of action
of NSAIDs is required.
Rat models offer many advantages over mouse models
for human disease [29]. Rats share 90% of their genome
with humans, and most currently identified disease-
linked human genes have equivalent ones within the rat
genome [30]. Compared to the mouse, rat physiology is
easier to monitor and closer to the human condition,
and rats are capable of learning a broader variety of
tasks [29]. Rats are also larger than mice and thus better
suited for surgeries and for use in the small-animal PET
system (μPET) in preclinical research and drug develop-
ment, which requires high spatial resolution.
In this study, we focused on the PGJ2-induced rat model
of neuroinflammation that exhibits progressive PD-like
pathology including dopaminergic neuronal loss in the
SNpc, microglia and astrocyte activation, and motor defi-
cits. Oral treatment with ibuprofen prevented most
PGJ2-induced PD-like pathology, indicating a potential
positive feedback loop between PGJ2 and COX-2. Our
analysis also suggests that upregulation of COX-2 and
L-PGDS could be important in the PGJ2 evoked
PD-like pathology. This pre-clinical rat model that we
developed could be highly valuable to identify biomarkers
and optimize therapeutics, such as DP2 antagonists or
L-PGDS inhibitors, to diminish neuroinflammation in
PD, circumventing the adverse side effects of cycloox-
ygenase inhibitors.
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Methods
Reagents and antibodies
PGJ2 (cat. # 18500) and ibuprofen (cat. # 70280) from Cay-
man Chemical (Ann Arbor, MI). PGJ2 (33.4 μg/injection)
was diluted in DMSO and then further diluted in PBS to a
final DMSO concentration of 17% for PGJ2 microinfusions.
The PGJ2 solutions were freshly prepared and stored for a
maximum of 2 h at 4 °C and in the dark. A 17% DMSO/
PBS was microinfused as the vehicle control. Primary anti-
bodies were: dopaminergic neurons [TH, tyrosine hydroxy-
lase, 1:1000, cat.# MAB318 (mouse, Millipore, Billerica,
MA) and cat.# Ab6211 (rabbit, Abcam, Cambridge, MA)];
microglia [Iba1, 1:500, cat.# 019-19741 (rabbit, Wako,
Richmond, VA) and 1:1000, cat.# ab139590 (chicken,
Abcam)]; astrocytes [GFAP, 1:1000, cat.# AB5541 (chicken,
Millipore)]; oligodendrocytes [GST-pi, 1:200, cat.# ab53943
(goat, Abcam)]; polyubiquitinated proteins [Ub, 1:200,
cat.# BML-PW8805 (mouse, Enzo Life Sciences, Farming-
dale, NY)]; phosphoS129 α-synuclein [pS129 α-syn, 1:200,
cat.# p1571-129 (rabbit, PhosphoSolutions, Aurora, CO)];
cyclooxygenase-2 [COX-2, 1:250, cat.# 160106 (mouse,
Cayman Chemical)]; prostaglandin D synthase [L-PGDS,
1:200, cat.# ab182141 (rabbit, Abcam)]; prostaglandin D2
receptor [DP2, 1:1000, cat.# PA5-20332 (rabbit, Thermo-
Fisher, Waltham, MA)]; 15-Hydroxyprostaglandin de-
hydrogenase [15-PGDH, 1:500, cat.# NB200-179, (rabbit,
Novus, Littleton, CO)]. Secondary antibodies—Alexa Fluor
568 (1:250, cat.# A11036, rabbit and cat.# A11031, mouse),
Alexa Fluor 488 (1:250, cat.# A11039, chicken), and Alexa
Fluor 350 (1:250, cat.# A10039, rabbit and cat.# A10035,
mouse)—were from Life Technologies (Carlsbad, CA).
Vectashield mounting medium (cat# H-1000, Vector La-
boratories, Burlingame, CA).
Rats
Sixteen-week-old Sprague Dawley male rats (N = 49;
body weight 376–533 g) were obtained from Taconic
Biosciences (Hudson, NY) and Envigo (Frederick, MD).
Rats were singly housed on a 12-h light/dark cycle,
maintained at 23 °C and 50–70% humidity, with food
and water available ad libitum. Rats were allowed to ac-
climate for 1 week before the baseline behavior assess-
ment and were 18 weeks old at the time of the first
injection.
Surgery and microinfusions
We followed the same procedures for the rats as de-
scribed in our previous study with mice [11]. Rats re-
ceived unilateral (right side) injections of vehicle
(DMSO) or PGJ2 into the SN. Briefly, at 18 weeks of
age, rats were anesthetized by isoflurane inhalation (in-
duction 2.5–3.5%, maintenance 2.5%) administered in
100% oxygen and placed into a digital stereotaxic instru-
ment (Model 51730D, Stoelting Co., Wood Dale, IL)
fitted with a rat anesthesia mask (Model 906, David Kopf
Instruments). A burr hole was drilled in the skull at
coordinates for the SNpc [31]: anterior-posterior (AP) =
− 5.6 mm; medial-lateral (ML) = + 2.0 mm; and dorsal-
ventral (DV) = − 8.0 mm relative to the bregma. All in-
jections were administered to the right SN, while the
contralateral (left) side served as an internal control. A
2-μl microinjection Hamilton syringe (7002 KH) with a
25-gauge needle was slowly inserted into the brain and
left in place for 2 min. Thereafter, 2 μl of solution was
infused at an injection rate of 0.2 μl/min (Quintessential
stereotaxic injector, Model 53311, Stoelting Co.). The
needle was left in place an additional 3 min to ensure
total diffusion of the solution. Following injection, the
needle was slowly removed and the incision was closed
with monofilament absorbable sutures (cat. # 038729;
Henry Schein, Melville, NY). After surgery, rats were re-
moved from the stereotaxic frame and administered a
subcutaneous injection of 1 cc Lactated Ringer’s solu-
tion, given wet palatable rodent chow, and kept in a
warm place to recover. Subsequent injections to the SN
were administered via the same drill hole established
during the first surgical procedure.
Ibuprofen administration
Ibuprofen can be administered to rats twice daily for up
to 80 days without adverse secondary side effects [32].
In our experiments rats were fed ibuprofen fortified
chow (ibuprofen: ~ 40 mg / kg body weight) chronically
starting the day after the first PGJ2 treatment. Ibuprofen
was added to Purina 5001 Rodent Chow (800 ppm, Re-
search Diets, Inc., New Brunswick, NJ). Individual intake
of ibuprofen was measured daily by weighing the given
and leftover chow per animal.
Experimental design
Rats in each group received two or four unilateral
DMSO or PGJ2 injections (once / week for two or four
consecutive weeks), starting at the age of 18 weeks. Rats
were randomly assigned to eight groups receiving the
following microinfusions (Fig. 1): (1) four × DMSO
alone (n = 4), sacrificed 4 weeks after the last injection;
(2) four × DMSO/PGJ2 (n = 5), sacrificed 4 weeks after
the last injection; (3) two × DMSO alone (n = 8), sacri-
ficed 4 weeks after the last injection; (4) two × DMSO/
PGJ2 (n = 6), sacrificed 4 weeks after the last injection;
(5) two × DMSO alone (n = 4), sacrificed 8 weeks after
the last injection; (6) two × DMSO/PGJ2 (n = 4), sacri-
ficed 8 weeks after the last injection; (7) two x DMSO
fed ibuprofen (n = 9), sacrificed 4 weeks after the last in-
jection; (8) two × DMSO/PGJ2 fed ibuprofen (n = 9),
sacrificed 4 weeks after the last injection.
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Rationale
Our first experimental group that received four PGJ2 in-
jections and was sacrificed 4 weeks after the last injec-
tion, exhibited severe dopaminergic (DA) neuronal loss
in the injected side of the SNpc, compared to the con-
trol DMSO-treated rats. In these rats, the motor deficits
in the PGJ2 group were highly significant compared to
its control group. Since the dopamine levels in the
brains of PD patients are reduced by 70–80% when their
motor symptoms occur [33], our PGJ2 rat model with
four injections successfully replicated the two major as-
pects of PD: DA neuronal loss with concomitant motor
deficits. We also aimed at modeling the mild/early path-
ology that worsens progressively, because the early stage
of PD is challenging to detect as it develops progres-
sively without any validated biomarkers. Thus, we used a
two-injection paradigm. In addition, as epidemiological
studies report a beneficial effect of NSAIDs in lowering
the risk of developing PD [26], we were interested in
testing whether ibuprofen-treatment would prevent/
minimize the mild/early pathology detected in our
two-injection PGJ2 rat model.
Behavior
Rats were tested for parkinsonian-like behavior 4 or
8 weeks after their last injection (Fig. 1). We used the
cylinder behavioral test that assesses spontaneous activ-
ity and limb use asymmetry in a novel environment.
This is considered a highly reliable and sensitive behav-
ioral test used to detect unilateral damage to the nigros-
triatal pathway [34]. An additional advantage of the
cylinder test is that inter-rater reliability is very high (r >
0.95) even with relatively inexperienced raters [34, 35].
Rats were placed in a transparent cylinder (11 in. in
diameter and 18 in. in height) and video-recorded for 5–
10 min depending on the activity level. A mirror was
placed at an angle underneath the raised cylinder to
allow the view of the back wall and the bottom of the
cylinder. To determine the extent of asymmetry, the use
of the left and right forelimb was counted during the
wall movements after a rear, and during the landings as
described in [34].
Forelimb use asymmetry is determined by the prefer-
ence toward the non-impaired forelimb for weight shift-
ing during spontaneous vertical exploration and landing.
These movements along the wall and landings after a
rear, were separately recorded and then averaged for
total asymmetry, to correct for variability as described in
[34, 35]. Each cylinder video was scored by two raters
blind to the experimental group to further reduce the
variability. Their scores were averaged and statistically
analyzed.
Adult Male Sprague-Dawley Rats
(18 weeks of age at the time of 1st injection)
PGJ2 [33.4 µg in (DMSO/PBS, 17 %)] or control (DMSO/PBS, 17 %) 
Unilateral injections (2 µl) into right SNpc
Baseline Behavior
(Cylinder test)
2X Injections: 
PGJ2 or
DMSO (Control)
4X Injections: 
PGJ2 or
DMSO (Control)
Behavior 
(NJ2 = 6; Nc = 8)
IHC (N = 3 / gp)
Behavior 
(NJ2 = 5; Nc = 4)
IHC (N = 3 / gp)
Behavior 
(NJ2 = 9; Nc = 9)
IHC (N = 3 / gp)
Behavior 
(N = 4 / gp)
IHC (N = 3 / gp)
+ 4 weeks + 4 weeks
+ IBP
+ 4 weeks+ 8 weeks
Fig. 1 Schematic representation of the experimental design for the rat PGJ2-treatment. Eighteen-week-old male Sprague Dawley male rats were
microinjected into the right SNpc as shown. Rats received two or four microinfusions of either DMSO (control; 17% in PBS) or PGJ2 (33.4 μg) in
2 μL DMSO/PBS at weekly intervals. Ibuprofen (IBP)-treated rats were fed IBP-mixed chow (800 ppm, ~ 40 mg/kg body weight) starting the day
after the first microinfusion and ending 5 weeks later. For all rats, motor behavior was assessed before the first injection and 4 weeks or 8 weeks
after the last injection. Following post-injection behavioral assessment, rats were perfused intracardially and the brains were removed for
immunohistochemical analyses. N = number of rats per group (gp). X = number of injections (once per week)
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Rodents display innate limb preference correlated to
endogenous nigrostriatal DA imbalance [36]. Thus, the
effect of the unilateral surgery on the behavior was mea-
sured as percent (%) change of the forelimb use asym-
metry post-surgery, compared to the baseline behavior
pre-surgery.
Immunohistochemistry
After the behavior analyses, rats were anesthetized (i.p.)
with ketamine (100 mg/kg) and xylazine (5 mg/kg), and
transcardially perfused with 4% paraformaldehyde in
PBS. The rat brains were removed, post-fixed overnight
at 4 °C, followed by cryoprotection (30% sucrose/PBS at
4 °C). Brains were sectioned in the coronal plane using a
freezing microtome at a thickness of 30 μm, and sections
were collected serially along the anterioposterior axis of
the SNpc [between − 4.56 mm and − 6.36 mm for the
SNpc; coordinates relative to bregma, as in [31]]. Tissue
series (eight series for the SNpc) were stored at 4 °C in
cryoprotectant (30% glycerol and ethylene glycol in PBS)
until use. Sections were processed free floating for im-
munohistochemical (IHC) analyses as described in [10].
At the end, sections were mounted on gelatin-subbed
glass slides with Vectashield. Sections were viewed under
a wide-field fluorescence microscope (Zeiss AxioImager)
using a Zeiss AxioCam MRm Rev. 3 camera connected
to a motorized stage; the software AxioVision 4 module
MosaiX was used to capture whole SN region mosaics
(× 10 magnification).
Exposure time for each channel was kept consistent
between sections. For each captured image, ZVI files
were loaded onto Image J (NIH, Bethesda, MD) and
converted to .tif files for use in optical density and
co-localization analyses. Each channel was analyzed to
an antibody specific threshold [37]. Pixel areas meeting
threshold intensity criteria were measured in delineated
SN regions.
The SNpc was delineated based on tyrosine hydroxy-
lase (TH+) staining at × 10 magnification while carefully
excluding cells within the ventral tegmental area (VTA).
For optical density (O.D.) analysis, three tissue sections
per treatment group were used for quantification. Non-
specific background density was corrected using ImageJ
rolling-ball method [38]. Data was expressed as O. D. ratio
from the ipsilateral SNpc over the contralateral.
Microglia analysis
Activated microglia exhibit a remarkable variety of
morphologies that can be associated with their particular
functions [39]. Using binary images of individual micro-
glia silhouettes, we distributed activated microglia into
three different groups according to their form factor
(FF) value (Fig. 4c), which is defined as 4π X area/perim-
eter2 [40]. Each of the three microglia groups is defined
as follows [39]: Ramified, FF: 0 to 0.5; actively engaged
in neuronal maintenance providing neurotrophic factors.
Reactive, FF: > 0.5 to 0.7; responsive to CNS injury.
Amoeboid, FF > 0.7 to 1; cell body is amorphous with
pseudopodia.
Stereology
Unbiased stereology analysis was conducted by scorers
blind to the experimental treatments as described in [11].
Total number of TH+ and Iba1+ cells were obtained with
the Zeiss AxioVision Release 4.8.2 Software unbiased ste-
reology programming (Carl Zeiss Group, Jena, Germany).
The outline of the SNpc delineated by TH+ staining [41]
was obtained at low (× 10) magnification. Within the de-
lineated SNpc area, depending on the anterioposterior
position of the coronal section, 5–11 sites were sampled
with the optical fractionator probe. For each brain, six
SNpc sections spaced 240 μm apart were used for the ana-
lyses. Cells were counted at × 40 magnification along the
AP axis, and at predetermined intervals [x-step = 230 μm;
y-step = 170 μm; 39,100 μm2; frame associated area (grid
size): horizontal = 226.057 μm, vertical = 168.380 μm;
38,063.478 μm2]. The z-depth was set at 20 μm to allow a
5-μm guard on the top and bottom surface of each section
to avoid error in case of tissue damage. Estimated cell
numbers in the whole SNpc were used for group compari-
son. Dopaminergic (DA) cell counts from the intact SNpc
were similar to a previous report [42]. Care was taken to
ensure that cells within the VTA were excluded from
SNpc quantification.
Statistical analyses
All data are expressed as the mean ± SEM. Statistical
analyses were performed with GraphPad Prism 6
(GraphPad Software, San Diego, CA). A p value < 0.05
was considered statistically significant. For group com-
parisons, we performed one-way analysis of variance
(ANOVA) followed by post hoc Tukey’s test for multiple
comparison. One-tailed Student’s T test was used to
compare means between two groups. Correlations be-
tween two variables were evaluated by linear regression
calculating the Pearson correlation coefficients.
Results
PGJ2 induces progressive dopaminergic neuronal loss in
the rat SNpc
Following our recently established PGJ2-induced mouse
model of PD-like pathology [10, 11], we investigated
in vivo the progressive effects of subchronic inflamma-
tion in rats. For this purpose, rats were administered
unilateral (right side) injections of PGJ2 to the SNpc for
2 or 4 weeks (once per week) as depicted in Fig. 1. Fol-
lowing behavioral analysis, the rats were sacrificed 4 or
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8 weeks post the last injection, and their brains analyzed
by immunohistochemistry.
To assess DA-specific neuronal damage, we performed
IHC staining for TH+. We used the unbiased optical
fractionator stereological method and compared the ra-
tio between the numbers of TH+ cells in the ipsilateral
SNpc over that in the contralateral side for each rat.
Rats, treated with four PGJ2-microinfusions and sacri-
ficed 4 weeks following the last injection, displayed in-
tense (74%) DA neuronal loss in the ipsilateral SNpc
(Fig. 2a, second panel, and 2b, right panel), compared to
DMSO-treated rats. We thus decided to reduce the
number of injections to two, with the hope of detecting
progressive DA neuronal loss. Indeed, DA neuronal loss
was significantly less upon two than four PGJ2 injections
(Fig. 2a, third and fourth panels, and 2b, right panel).
Moreover, DA neuronal loss was progressive, as it sig-
nificantly [t(4) = 4.65; p = 0.005] intensified 8 weeks
compared to 4 weeks post-injection. Compared to
DMSO-treatment, DA neuronal loss was 32% and 20%
respectively, 8 and 4 weeks following PGJ2-treatment.
The contralateral SNpc served as the uninjected control
for each rat, and no significant differences were detected
among groups (Fig. 2a, b, left panel).
The DA neurons in the VTA were less affected than
those in the SNpc (Fig. 2c). Immunostaining for
neuron-specific nuclear protein (NeuN) decreased sig-
nificantly in the SNpc, following PGJ2 administration
[t(4) = 5.76; p = 0.002], thus corroborating that the loss
in TH immunostaining was due to the degeneration of
DA neurons and not to TH depletion (Fig. 2d, left
panel). The decrease in NeuN+ immunoreactivity in the
VTA and SN pars reticulata (SNpr) was either
non-significant or less than in the SNpc (Fig. 2d, right
panel).
PGJ2-treated rats develop parkinsonian-like motor deficits
in a progressive manner
Clinically, PD is characterized by the development of
motor deficits caused by the loss of dopamine in the SNpc
[43–45]. To determine the effect of PGJ2 treatment on
motor performance, we measured the forelimb use asym-
metry with the cylinder test which is considered a sensi-
tive measure of the degree of unilateral nigrostriatal
damage [46]. Unilateral injections into the right SN should
cause forelimb impairment in the contralateral (left) side
and encourage the use of the ipsilateral, right-forelimb,
thus reflecting a change in nigrostriatal DA. For each ani-
mal, the percent (%) change in asymmetry between pre
(baseline) and post-injection was calculated. The mean ±
SEM for each treatment group was used for statistical
analysis.
Weekly PGJ2-microinfusions induced a gradual and
significant bias toward use of the ipsilateral over the
contralateral forelimb when compared to the DMSO
controls (Fig. 3a). The Pearson correlation coefficient in-
dicates a significant negative correlation between ipsilat-
eral forelimb use and the number of ipsilateral TH+
cells in the SNpc in the PGJ2-treated rats (r2 = 0.6, p =
0.007; Fig. 3b, right panel). Such correlation was absent
for the DMSO-treated rats (r2 = 0.047, p = 0.287; Fig. 3b,
left panel).
These behavioral assessments together with the IHC
data for the TH+ DA neurons (Fig. 2) strongly support
that PGJ2 induces the development of PD-like pathology
in a progressive manner over the period of 8 weeks
post-treatment.
PGJ2-treatment alters the morphological/functional
properties of activated microglia in the rat SNpc, but
does not change microglia total numbers in the same
area
We analyzed the number of microglia in DMSO and
PGJ2-treated rats. The intact contralateral SN served as
the control for each rat. We thus evaluated and com-
pared the activated microglia numbers for each rat, as a
ratio between ipsilateral over contralateral sides.
Due to the surgical procedure, SN injections of DMSO
alone increased microglia activity as assessed by Iba1 im-
munostaining. Compared to DMSO-treatment, PGJ2 did
not significantly [t(4) < 0.449); p > 0.33] change the over-
all numbers of activated microglia, (Fig. 4a, b).
However, based on the FF values, we observed a signifi-
cant rise in reactive [t(4) = 2.74; p = 0.026] and amoeboid
[t(4) = 4.74; p = 0.005] microglia in PGJ2-treated rats com-
pared to the DMSO-treated ones (Fig. 4d). The rise in re-
active and amoeboid microglia was only detected in rats
treated with two PGJ2 injections and sacrificed 4 weeks
post-injection (Fig. 4d). The microglia rise was not appar-
ent in the PGJ2-treated rats 8 weeks post-injection. The
plotted values represent the ratio between ipsilateral over
contralateral sides for each rat, normalized to the ramified
microglia, which are the ones associated with normal
physiological function.
PGJ2-treatment increases astrocyte reactivity in the rat
SNpc
Astrocytes in the brain become reactive under patho-
logical conditions, including in neurodegenerative dis-
eases [47]. Under these conditions, reactive astrocytes
overexpress GFAP and undergo morphological changes
(hypertrophy and process remodeling) [47].
Our studies demonstrate that, compared to DMSO, rats
that received two PGJ2 microinjections exhibited in the
SNpc, a significant [t(4) = 2.14; p = 0.049] increase in astro-
cyte reactivity 8 weeks, post-injections (Fig. 5a, b). The
astrocyte reactivity in the other groups of PGJ2-treated rats
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Fig. 2 Progressive dopaminergic neuronal loss in the SNpc upon successive intranigral PGJ2 microinjections. a Representative coronal sections of
the ventral midbrain depicting dopaminergic neurons. TH-immunoreactivity was strong in the VTA and SNpc (rectangle) of control (DMSO) rats.
TH-immunoreactivity decreased in the ipsilateral SNpc of rats receiving two (2X) or four (4X) PGJ2 injections. Dopaminergic neurons in the VTA
were less affected. Scale bar = 500 μm. b The extent of PGJ2-induced damage was assessed by calculating the total number of TH+ neurons
(mean ± SEM) in the SNpc using unbiased stereology as described in Materials and Methods. No significant differences in TH+ neurons were
observed in the contralateral SNpc of the different groups of rats. TH+-immunoreactivity decreased in a gradual manner in the ipsilateral SNpc of
rats receiving two (2X) or four (4X) PGJ2 injections and at 4 weeks or 8 weeks post-injections of two (2X) PGJ2 injections. c PGJ2-induced damage
in the VTA was measured by TH+ area (mean ± SEM). Dopaminergic neurons in the VTA were less affected than in the SNpc. d Neuronal loss in
the SNpc, VTA, and SNpr were compared by NeuN+ area (mean ± SEM). NeuN-immunoreactivity decreased significantly in the SNpc, but less in
the VTA and not significantly in the SNpr of PGJ2-injected rats compared to controls (DMSO-treated). Black circles, control, DMSO-treated rats; red
circles, PGJ2-treated rats. Statistical significance was estimated with one-way ANOVA (b, left), and the Student’s T test (b, right, c and d) to compare
DMSO and PGJ2-treated groups and between two PGJ2-treated groups. The p values in red indicate statistical significant (< 0.05) difference from
DMSO-injected rats. N = 3 rats per group. X = number of injections (once per week)
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[2X, 4 weeks, t(4) = 1.18; p = 0.152; 4X, 4 weeks, t(4) = 1.04;
p = 0.179] was non-significantly different from controls.
Detection of intraneuronal aggregate-like inclusions of
ubiquitinated proteins and phosphorylated (pS129) α-
synuclein in SNpc DA neurons of rats treated with PGJ2
The accumulation of proteinaceous intraneuronal in-
clusions known as Lewy bodies in SNpc DA neurons is
one of the hallmarks of PD [48]. These inclusions con-
tain ubiquitinated proteins [49] as well as α-synuclein
phosphorylated at S129 (pS129 α-syn) [50]. We ad-
dressed this aspect of PD (Fig. 6a for ubiquitinated pro-
teins, and 6b for pS129 α-syn, both quantified in 6c) by
focusing on the TH+ DA neurons of the SNpc. Since
our preceding studies already demonstrated the pro-
gressive nature of the PGJ2-induced rat model, for this
analysis and all subsequent studies, we focused only on
four experimental paradigms: rats treated with two in-
jections or four injections of DMSO or PGJ2, and sacri-
ficed 4 weeks post-injections.
Regardless of the number of PGJ2 injections, there
was a shift from a diffuse distribution of ubiquitinated
proteins and pS129 α-syn detected in TH+ neurons of
DMSO-treated rats, to more of an aggregated appear-
ance observed in the PGJ2-treated rats (white arrows,
Fig. 6a, b). Moreover, we established that only treatment
with four (not two) PGJ2 injections induced a significant
[t(4) = 3.22; p = 0.016] elevation in the levels of ubiquiti-
nated proteins in the few spared TH+ neurons (Fig. 6c,
left panel). The levels of pS129 α-syn also increased
under these conditions, almost reaching statistical sig-
nificance [t(4) = 1.63; p = 0.089; Fig. 6c, right panel].
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Fig. 3 Correlation between behavioral deficits and dopaminergic (TH+) neuronal loss in the SNpc induced by successive PGJ2 microinfusions.
a All groups of rats treated with PGJ2 (shades of red circles) exhibited behavioral deficits. When compared to DMSO-treated rats (white, gray
and black circles), those treated with 2X and 4X PGJ2 significantly increased usage of the ipsilateral forelimb as assessed by the cylinder test (see
Materials and Methods). Statistical significance was estimated with the Student’s T test to compare DMSO and PGJ2-treated groups, and between
two PGJ2-treated groups. The p values in red indicate the values that are significantly (< 0.05) different from DMSO-injected rats. N = 4 to 8 rats
per group. b In the PGJ2-treated but not in the control (DMSO) rats, dopaminergic neuronal loss (TH+) in the ipsilateral SNpc (x-axis) inversely
correlates with forelimb usage asymmetry (y-axis). X = number of injections (once per week)
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Cell-type distribution and levels of key factors of the
prostaglandin D2/J2 pathway
Up to now, our findings corroborated that PGJ2-treated
rats develop PD-like pathology in a progressive temporal
manner. We wanted to take our in vivo investigation
one step forward and address the impact of PGJ2 on the
cell-type distribution and levels of key factors of the
prostaglandin D2/J2 pathway observed during the
4-week window, including COX-2, the PGD synthase
L-PGDS, the PGD2/J2 receptor DP2, and the prostaglan-
din dehydrogenase 15-PGDH (Fig. 7). We would like to
highlight that the cell-type distribution and levels of
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Fig. 4 Successive PGJ2 microinfusions induce microglia morphological and functional changes detected post-mortem. a TH (blue, dopaminergic)
and Iba1 (red, microglia) immunostaining shows a gradual loss of dopaminergic neurons and gain of activated microglia in the ipsilateral SNpc.
Scale bar = 50 μm. b The overall numbers of microglia in the ipsilateral SNpc did not significantly differ between DMSO (control) and PGJ2–treated
rats. c Microglia morphologic changes represented by the form factor (FF) calculated as 4π X area/perimeter2. d The number of reactive and
amoeboid microglia significantly increased in the ipsilateral SNpc of rats receiving two (2X) PGJ2 injections at 4 weeks but not at 8 weeks
post-injections, compared to controls (DMSO-treated). Values on the y-axis represent the ratios between the ipsilateral SNpc over the contralateral,
normalized to the number of ramified microglia. Black circles, control, DMSO-treated rats; red circles, PGJ2-treated rats. Statistical significance was
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significant (p < 0.05) difference from DMSO-injected rats. N = 3 rats per group. X = number of injections (once per week)
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these four factors have never been investigated under
control or stress conditions in the SNpc in relation to
PD, at least to our knowledge. Like for the ubiquitinated
proteins and α-syn studies, we focused only on four ex-
perimental groups: rats treated with two injections or
four injections of DMSO or PGJ2, and sacrificed 4 weeks
post-injections.
We examined by immunocytochemistry, the distribu-
tion and levels of these factors in DA neurons and
microglia in the SNpc by assessing the optical density ra-
tio or co-localization of each of these factors with TH+
or Iba1+, respectively. There was no significant differ-
ence in the levels of these four factors in DA neurons
(Fig. 7a–d, left) in rats that received 2× PGJ2 injections
(red circles) compared to controls (DMSO-treated, black
circles). In contrast, COX-2, L-PGDS, and 15-PGDH
levels increased significantly in the DA neurons of
PGJ2-treated rats that received four injections, when
compared to controls (Fig. 7a, b, d, left). The DP2
receptor levels were stable in control and PGJ2-treated
(4×) rats (Fig. 7c).
In regard to microglia, there was more variation in
their responses to PGJ2-treatment. Starting with COX-2,
we observed a rise in its levels in rats treated twice with
PGJ2, but not in those treated four times with PGJ2,
compared to controls (Fig. 7a, right). For L-PGDS, sig-
nificant increases were detected in both groups of
PGJ2-treated rats compared to controls (Fig. 7b, right).
Notably, DP2 receptors in microglia were almost
non-existent or expressed at very low levels (Fig. 7c,
right, and Table 1). When considering ipsilateral and
contralateral SNpc separately, values representing the
number of microglia exhibiting co-localization of the
other three factors (COX-2, L-PGDS, 15-PGDH) with
the microglia marker Iba1+, varied between 117 and 250
(not shown). However, for the DP2 receptor, these values
ranged from 17 to 50 (Table 1); thus, they were 2 to 15
times lower. We suspect that in the microglia case,
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co-localization of DP2+/Iba1+ immunostaining is a para-
dox and is most likely due to the proximity of a micro-
glia to a DA neuron.
The microglia levels of the prostaglandin dehydrogen-
ase 15-PGDH did not change in any of the control or
PGJ2-treated groups of rats (Fig. 7d, right). We found
that this enzyme was expressed in another cell type, i.e.,
oligodendrocytes. The latter were detected in the SNpc
of all groups of rats with the marker for mature oligo-
dendrocytes, the pi form of glutathione-S-transferase
(GST-pi, Fig. 7e).
Ibuprofen prevents most of the PD-like pathology
developed in PGJ2-treated rats
Ibuprofen (IBP) is an NSAID that inhibits COX-1 and
COX-2, thus reducing the synthesis of all prostaglandins
[1, 51]. We previously demonstrated that PGJ2 induces
COX-2 upregulation in neuronal cells [25], potentially
establishing a positive feedback loop between PGJ2 and
COX-2. This positive feedback effect of PGJ2 on COX-2
could promote the transition from acute to chronic neu-
roinflammation and consequently promote progressive
PD pathology.
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two (2X) and four (4X) PGJ2 microinjections. Dopaminergic neurons in the SNpc of PGJ2-treated rats exhibit aggregate-like ubiquitin conjugates
and pS129 α-synuclein neuronal inclusions (white arrows). Scale bar = 50 μm. c Values on the y-axis represent the optical density (OD) ratios
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Fig. 7 Effects of successive PGJ2 microinfusions on the following factors of the PGD2/J2 prostaglandin pathway: COX-2 (a), L-PGDS (b), DP2
receptor (c), and 15-PGDH (d), all in dopaminergic neurons and microglia, and 15-PGDH also in oligodendrocytes (e). Immunostaining for COX-2
(red in a), L-PGDS (red in b), DP2 (red in c), 15-PGDH (red in d and e), TH+ neurons (blue in a–d), Iba1+ microglia (green in a–d), and GST-pi+
oligodendrocytes (green in e) at 4 weeks after two (2X) and four (4X) PGJ2 microinjections. Scale bar = 50 μm. a COX-2 is significantly increased
in dopaminergic neurons from rats receiving four (4X) PGJ2 injections compared to controls. Co-localization of COX-2 and Iba1 is greater in
microglia from rats receiving two (2X) PGJ2 injections than in controls. b L-PGDS is significantly increased in dopaminergic neurons from rats
receiving four (4X) PGJ2 injections than in controls. Co-localization of L-PGDS and Iba1 is greater in microglia from rats receiving two (2X) and
four (4X) PGJ2 injections than in controls. c DP2 levels remain stable in dopaminergic neurons from all treatment groups, but DP2+ staining is
almost absent in microglia. d 15-PGDH expression is increased in dopaminergic neurons from rats receiving four (4X) PGJ2 injections, but not in
microglia. e 15-PGDH is highly expressed in SNpc oligodendrocytes from all groups of rats. Values on the y-axis represent the optical density (OD,
normalized to TH, left graphs), or co-localization (normalized to Iba1, right graphs) ratios between ipsilateral SNpc over the contralateral. Black
circles, control, DMSO-treated rats; red circles, PGJ2-treated rats. Statistical significance was estimated with Student’s T test to compare DMSO and
PGJ2-treated groups. The p value in red indicates significant (p < 0.05) difference from DMSO-injected rats. N = 3 rats per group. X = number of
injections (once per week)
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To determine the contribution of the cyclooxygen-
ase pathway to the PGJ2-induced PD-like pathology
in vivo, we administered IBP to the PGJ2-treated rats.
The four groups of rats (2X DMSO ± IBP and 2X
PGJ2 ± IBP) were analyzed at 4 weeks post the last
PGJ2 treatment, with the cylinder test and immuno-
chemistry. Preventive IBP-treatment starting the day
after the first surgery ameliorated all PD-like path-
ology induced by PGJ2, except for reactive astrocytes
(Fig. 8).
It is clear that IBP reduced DA neuronal loss
(Fig. 8a, b), as well as reactive and amoeboid micro-
glia rise (Fig. 8a, c, d) in the SN, and prevented the
bias toward use of the ipsilateral over the contralat-
eral forelimb (Fig. 8f ). There was no statistical differ-
ence between DMSO and PGJ2-treated rats that were
fed IBP in relation to these four parameters: numbers
of TH+ cells (Fig. 8b), reactive (Fig. 8c) and amoeboid
(Fig. 8d) microglia, and bias toward use of the ipsilat-
eral over the contralateral forelimb (Fig. 8f ). These
results support the preventive effects of IBP in terms
of PD-like pathology induced by PGJ2, a mediator of
inflammation.
In contrast, IBP administration significantly [t(4) =
2.14; p = 0.05] increased astrocyte reactivity upon PGJ2-
treatment, compared to DMSO-treatment (Fig. 8a, e).
Thus, we show that PGJ2-treatment causes sustained
astrogliosis, which is not alleviated by the IBP treatment
(Figs. 5 and 8a, e). We should note that the role of astro-
cytes in PD pathology is ambiguous as activated
astrocytes can produce both pro-inflammatory and
anti-inflammatory factors, as well as neurotoxic and
neurotrophic factors [52]. The types of reactive astrocytes
that are induced by PGJ2 ± IBP remain to be investigated.
Discussion
The frequent failure of potential new treatments in clin-
ical trials suggests that current PD models may not ex-
hibit the critical and/or complete set of PD traits
experienced in humans. Other types of animal models
relevant to PD need to be developed. Compelling evi-
dence supports that neuroinflammation [1–5], and in
particular the cyclooxygenase pathway, plays a central
role in PD [6–8]. However, very few studies address how
prostaglandin products of cyclooxygenases redirect
cellular events to promote neurodegeneration in PD. In
the current studies, we developed a non-transgenic rat
model of neuroinflammation by microinfusing PGJ2 uni-
laterally into the right SNpc. The PGJ2-treated rats dis-
played progressive DA neuronal loss that correlates with
motor deficits, as well as gliosis including increases in acti-
vated microglia and reactive astrocytes. The DA neurons
in the SNpc developed aggregate-like ubiquitinated pro-
tein and pS129 phosphorylated α-synuclein deposits. All
of these traits are characteristic of human PD-pathology.
This new PGJ2-induced rat model offers several ad-
vantages over other PD models. In the first place, we
identified elements of the prostaglandin D2/J2 pathway
that may be novel therapeutic targets for PD, down-
stream of the cyclooxygenase pathway (Fig. 9). Our stud-
ies show for the first time the distribution and levels of
these elements in DA neurons and microglia of the
SNpc. Although our studies do not address whether DP2
receptors or L-PGDS directly mediate the PGJ2 effects
in the rat model, we propose that neuronal DP2 receptor
antagonists and L-PGDS inhibitors could be novel drugs
to prevent/diminish PD pathology associated with neu-
roinflammation (Fig. 9).
DP2 receptors bind PGD2 and PGJ2 with similar affin-
ities (nanomolar range) [53, 54]. DP2 receptors are
Gi-protein-coupled-receptors, and their activation down-
regulates cAMP and increases intracellular calcium levels
[55, 56]. We found that DP2 receptors are abundantly
expressed in DA neurons of the SNpc, while almost lack-
ing in microglia. Thus, PGD2/J2 released from activated
microglia could lead to aggravated DA neuronal damage
via DP2 receptor activation. On the other hand, DP2 in-
hibition could ameliorate neuronal dysfunction. In sup-
port of neuroprotection accomplished by blocking DP2
receptors, DP2 antagonists [CAY10471 and its BAY-u3405
(ramatroban) analog] were found to attenuate pain in a
peripheral nerve injury rat model [57]. In addition,
CAY10471 was shown to increase survival of rat hippo-
campal neurons exposed to aluminum [58]. In contrast,
DP2 activation was shown to potentiate injury in rat hip-
pocampal neuronal cultures and organotypic slices [7, 16].
Based on all of these findings, we propose that DP2
antagonists may protect DA neurons from the neuro-
toxic effects of activated microglia in PD, in particular
SNpc DA neurons, which exhibit low calcium buffer-
ing capacity [59].
In regard to L-PGDS, this enzyme is responsible for
most PGD2 synthesis in the brain and is one of the most
abundant cerebrospinal fluid (CSF) proteins [60], repre-
senting ~ 3% of total CSF proteins [61]. We established
that PGJ2-treated rats display increased L-PGDS levels,
suggesting that L-PGDS inhibitors may protect neurons
from PGD2/J2-induced PD-pathology. The following
studies support this premise. Cortical neurons derived
Table 1 Low detection levels of DP2 and Iba1 co-localization in
microglia. N = 3 rats per group. X = number of injections (once
per week)
# of Co-Lo DP2
& Iba1 (SNpc)
2×, 4 weeks 4×, 4 weeks
Control PGJ2 Control PGJ2
Contralateral 29.7 ± 2.9 21.7 ± 2.3 17.3 ± 4.7 30.7 ± 2.7
Ipsilateral 24.3 ± 6.0 20.7 ± 0.3 22.3 ± 1.5 50.7 ± 3.9
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from L-PGDS null mice exhibited higher cell viability
and less accumulation of ubiquitinated proteins in re-
sponse to hypoxic conditions, than those derived from
L-PGDS heterozygous mice [17]. L-PGDS was also iden-
tified as the major apoptotic factor in plasma of AD
patients [62]. In addition, in vivo and in vitro studies
demonstrated that L-PGDS promotes reactive gliosis re-
lated to brain pathology [63, 64]. Alterations in L-PGDS
levels in the CSF were detected in at least 20 idiopathic
PD patients compared to 100 controls [65]. These
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L-PGDS changes could indicate pathology at the cellular
level with an impact on PGD2/J2 levels and also correl-
ate with disease symptoms [65]. Based on all of these
studies, we propose that L-PGDS could be considered a
PD biomarker with predictive value [65] and could also
be explored as a potential drug target for therapeutic
intervention in neuroinflammation-driven PD.
Prostaglandins are unstable thus act as autocrine or
paracrine ligands by exerting their effects near their sites
of synthesis [66]. The enzyme 15-PGDH inactivates
prostaglandins in the cytoplasm. Therefore, cyclooxy-
genases/synthases and 15-PGDH control prostaglandin
cellular levels by opposite means. Although 15-PGDH
metabolizes neuroprotective as well as neurotoxic pros-
taglandins, higher 15-PGDH levels may be beneficial
under conditions where the effects of neurotoxic prosta-
glandins outweigh those of the neuroprotective ones
[67]. We found that in PGJ2-treated rats, the levels of
15-PGDH expression in DA neurons seemed equivalent
to those in control rats. In addition, we detected
15-PGDH in SNpc oligodendrocytes identified with
GST-pi, the pi form of glutathione-S-transferase. The
presence of 15-PGDH in oligodendrocytes may repre-
sent a protective mechanism to counteract the increased
oligodendrocyte vulnerability to excitotoxic death associ-
ated with COX-2 up-regulation following, for example,
glutamate receptor activation [68].
The second advantage offered by the PGJ2-induced rat
model is related to animal models that recapitulate the
disease phenotype with some degree of fidelity. These
animal models should be valuable for developing and
testing new or repurposed therapeutic agents as well as
MRI and PET imaging tracers [69]. Our current studies
show that when administered prior to symptom develop-
ment, ibuprofen, which inhibits COX-1 and COX-2, pre-
vented most of the PGJ2-induced PD-like pathology.
This finding is important because it demonstrates that
PGJ2-induced neurodegeneration is mediated in part by
activation of the cyclooxygenase pathway that could lead
to chronic inflammation. In addition, our data support
that NSAIDs can be instrumental in preventing DA neu-
rodegeneration associated with inflammation. The
Fig. 9 Scheme depicting novel and previously tested therapeutic agents (in green) that could have potential to treat PD. (1) DP2 receptor antagonists:
in the SNpc, DP2 receptors were detected in dopaminergic neurons but not in microglia. DP2 receptor activation leads to a decrease in cAMP and an
increase in calcium. These effects mediate neurotoxicity induced by DP2 receptor activation. Thus, DP2 receptor antagonists could potentially prevent
DA neurodegeneration. (2) COX-inhibitors: Ibuprofen, a COX inhibitor, prevented many of the sequelae induced by the PGJ2 treatment. Our data
support the epidemiological studies that report the beneficial effect of NSAIDs in lowering the risk of developing PD. (3) L-PGDS inhibitors: in the brain,
this enzyme synthesizes PGD2 from PGH2. PGD2 and its metabolite PGJ2 can be neurotoxic. Thus, decreasing L-PGDS activity will lower PGD2 levels
and could prevent or diminish the neurotoxic effects of PGD2/J2 on dopaminergic neurons. COX 1 and 2, cyclooxygenase 1 and 2; L-PGDS, lipocalin
prostaglandin D synthase; 15-PGDH, 15-hydroxyprostaglandin dehydrogenase; PPARγ, peroxisome proliferator-activated receptor gamma; PET, positron
emission tomography (see text for details)
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conflicting epidemiological and clinical results on the
potential use of NSAIDs to treat PD could be due to var-
iations in (a) length of treatment (longer in epidemio-
logical and shorter in clinical studies), and/or (b) disease
stage at the start of treatment (pre-pathology in epi-
demiological and post-pathology in clinical studies),
reviewed in [70]. The PGJ2-induced rat model was also
used to test a variety of PET tracers with the major
intention of assessing in vivo the progression and
spreading of neuroinflammation, (manuscript in prepar-
ation). These latter studies could help establish the opti-
mal timeline for therapeutic intervention, to prevent PD
pathology linked to neuroinflammation.
Thirdly, we show that the PGJ2-induced PD-like path-
ology in rats developed in a progressive manner, as it
worsened with time up to 8 weeks post the second PGJ2
injection, the latest time-point that we analyzed. In ani-
mal models, the progressive nature of PD neurodegener-
ation is a hard-to-mimic aspect of this disorder. Toxin
and pharmacologically induced PD models such as
6-hydroxydopamine, 1-methyl-1,2,3,6-tetrahydropiridine
(MPTP), paraquat and rotenone exhibit motor symp-
toms, but they are often related to massive and rapid de-
generation of the nigrostriatal pathway [71]. A similar
phenomenon is observed in lipopolysaccharide (LPS)-me-
diated models of PD, used to address the link between
neuroinflammation and PD pathology. LPS administered
intracranially into the SN, striatum or globus pallidus
causes DA neuronal loss within 24 h that persists at the
same level up to 30 days, therefore not mimicking the
progressive nature of PD pathology [72, 73]. Single sys-
temic administration of LPS causes progressive dopa-
minergic neuronal loss, although microglia activation is
not specific to the SN, being detected in a variety of
brain regions [74].
Fourthly, we established that PGJ2 has similar neuro-
toxic effects in rats and mice, as we previously de-
scribed for the PGJ2-induced mouse model that
displayed comparable PD-like pathology [10, 11]. This
is not the case for all drug-based PD models, some of
which are species-specific. For example, rats are resist-
ant to MPTP and the MPTP-sensitivity differs widely
among various strains of mice [75]. Moreover, not all
PD animal models exhibit DA neuronal degeneration
and correlated motor deficits, as we detect in the
PGJ2-induced rat model. For example, PD models
based on genetic risk factors such as Parkin, PINK1
and LRRK2 show little or no nigrostriatal degeneration
and motor symptoms [76]. Most PD models, transgenic
and non-transgenic, exhibit some level of neuroinflam-
mation usually detectable early and sometimes even
pre-symptom development [77, 78]. It is thus advanta-
geous to address novel targets of neuroinflammation,
such as we do in the current study.
Conclusions
Collectively, this is the first study to address the nigral
dopaminergic and microglial distribution and levels of
factors of the PGD2/J2 pathway in rodents. We focused
on the PGJ2-induced rat model of neuroinflammation
that exhibits progressive PD-like pathology, which is a
hard-to-mimic aspect of this disorder. Comparisons
between control and PGJ2-treated rats and the benefits
of the ibuprofen treatment support that upregulation of
COX-2 and L-PGDS may be important in the PGJ2-
evoked PD-like pathology. Moreover, future mechanistic
and pharmacological studies including this PGJ2-induced
pre-clinical rat model will be highly valuable for identify-
ing biomarkers and optimizing therapeutics, such as
DP2 antagonists and L-PGDS inhibitors, which target
neuroinflammation-driven PD circumventing the ad-
verse side effects of cyclooxygenase inhibitors.
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